Stories > Lilly's Missed Opportunity in Weight-Loss Drugs

Lilly's Missed Opportunity in Weight-Loss Drugs

Amgen's Obesity Prospects and Q4 Results...

Biden's $35 Insulin Price Cap

Biopharma Innovations in Obesity and Mus...

Anti-Obesity Meds' Impact on Allurion Pr...

FDA Finds No Preliminary Link Between Oz...

FDA Warns of Counterfeit Ozempic